News
Ahead of ASCO data drop, AZ gets key Imfinzi approval
AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.
News
November date set for FDA decision on Sanofi's Gaucher drug
The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
News
AbbVie's Immunogen buy delivers rare cancer drug approval
AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.
News
FDA delays verdict on AZ breast cancer drug
After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.
Sales & Marketing
Sponsored
Solution Spotlight: InConcert for pre-launch
Inizio InConcert brings together engagement data, field insight, and clinical indicators to help teams see how readiness is taking shape.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
